Compare Ascendis Pharma A/S (ASND) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs PPG Industries, Inc. — how do they compare? Ascendis Pharma A/S trades at $264.44 (market cap $17.74B), while PPG Industries, Inc. trades at $115.07 (market cap $26.03B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.43% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PPG | |
|---|---|---|
Market Cap | $17.74B | $26.03B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $131.56 |
52-Week Low | $163.32 | $94.34 |
Enterprise Value | $18.11B | $32.13B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PPG Industries trades at $116.76, up 0.69% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.83% net margin and 21.09% ROE, supported by $15.88B in 2025 revenue. Analysts show a 52.63% buy consensus with a $131.75 price target. Recent news highlights innovation in aerospace and marine coatings, though sentiment remains mixed amid modest revenue growth.
PPG offers solid fundamentals and dividend stability but faces headwinds from volume softness and margin pressure. The stock's valuation at a P/E of 16.73 appears reasonable, yet near-term catalysts are limited. Risks include economic sensitivity and competitive pressures, while institutional support and consistent cash flow provide a floor. The outlook is neutral with upside dependent on execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
